Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) and Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.
Profitability
This table compares Tvardi Therapeutics and Dr. Reddy’s Laboratories’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tvardi Therapeutics | N/A | -182.46% | -106.06% |
| Dr. Reddy’s Laboratories | 8.56% | 7.91% | 5.29% |
Volatility and Risk
Tvardi Therapeutics has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Dr. Reddy’s Laboratories has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.
Valuation and Earnings
This table compares Tvardi Therapeutics and Dr. Reddy’s Laboratories”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tvardi Therapeutics | N/A | N/A | -$18.21 million | ($2.68) | -0.44 |
| Dr. Reddy’s Laboratories | $329.84 billion | 0.04 | $456.00 million | $0.37 | 39.91 |
Dr. Reddy’s Laboratories has higher revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy’s Laboratories, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings for Tvardi Therapeutics and Dr. Reddy’s Laboratories, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tvardi Therapeutics | 1 | 0 | 6 | 1 | 2.88 |
| Dr. Reddy’s Laboratories | 1 | 3 | 2 | 0 | 2.17 |
Tvardi Therapeutics currently has a consensus price target of $9.40, suggesting a potential upside of 696.61%. Dr. Reddy’s Laboratories has a consensus price target of $492.90, suggesting a potential upside of 3,238.30%. Given Dr. Reddy’s Laboratories’ higher possible upside, analysts plainly believe Dr. Reddy’s Laboratories is more favorable than Tvardi Therapeutics.
Insider & Institutional Ownership
44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Dr. Reddy’s Laboratories shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy’s Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Dr. Reddy’s Laboratories beats Tvardi Therapeutics on 8 of the 14 factors compared between the two stocks.
About Tvardi Therapeutics
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases. The company’s research focuses on STAT3, a protein involved in processes that can contribute to tumor growth and fibrosis. Its lead drug candidate, TTI-101, is an oral small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. Tvardi is also advancing additional drug candidates based on its STAT3 research platform. Headquartered in The Woodlands, Texas, Tvardi is focused on research and clinical development; its investigational candidates are not established commercial products.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based pharmaceutical company that develops, manufactures and markets generic medicines, active pharmaceutical ingredients (APIs) and other healthcare products. Its portfolio includes branded and unbranded generics, biosimilars and select proprietary medicines across therapeutic areas such as oncology, gastroenterology, cardiovascular care and diabetes. Founded in 1984 by Kallam Anji Reddy, the company is headquartered in Hyderabad, India. It serves patients and customers in India and international markets, including the United States, Europe and countries in Russia and the Commonwealth of Independent States.
Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
